3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
15
fludarabine
12
Mycophenolic Acid
10
Standard of Care
9
Whole-Body Irradiation
7
Tacrolimus
7
venetoclax
6
Specimen Handling
6
Sirolimus
6
Practice Guidelines as Topic
6
trametinib
5
Melphalan
5
fludarabine phosphate
4
Mesna
4
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Biopsy
4
Behavior Therapy
4
Azacitidine
4
Thiotepa
3
Peripheral Blood Stem Cell Transplantation
3
GSK2636771
3
Educational Status
3
Crizotinib
3
Busulfan
3
thymoglobulin
2
talquetamab
2
ruxolitinib
2
palbociclib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Inosine Monophosphate
×
90 days
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled